Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of American Depositary Shares (ADS) of Mereo BioPharma Group plc, covering the period from June 5, 2023, to December 26, 2025, due to alleged misleading statements regarding the company's clinical studies [1][5][6]. Group 1: Lawsuit Details - The lawsuit claims that Mereo BioPharma provided investors with optimistic information about the Phase 3 Orbit and COSMIC studies for setrusumab, suggesting it would reduce annualized fracture rates [5]. - It is alleged that while making these positive statements, Mereo BioPharma concealed material adverse facts about the Phase 3 programs, which did not meet their primary endpoints [6]. - The misleading information led to investors purchasing Mereo's ADSs at artificially inflated prices, resulting in damages when the true details were revealed [6]. Group 2: Participation Information - Investors who purchased Mereo ADSs during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, interested parties can visit the provided link or contact the law firm directly for more information [3][7]. - A lead plaintiff must be appointed by April 6, 2026, to represent other class members in the litigation [1][3]. Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has consistently ranked highly in securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Insights - Spark Energy Minerals Inc. has reported promising results from its maiden Reverse Circulation drill program at the Arapaima Project in Brazil's Lithium Valley, indicating a laterally continuous critical minerals system [1][9]. Rare Earth Elements (REE) Highlights - All five drill holes intersected broad rare earth mineralization, with Magnet Rare Earth Oxides (MREO) comprising up to 33% of Total Rare Earth Oxides (TREO) [2][3][4]. - The consistent mineralization across all holes suggests a coherent and laterally continuous mineralized system rather than isolated high-grade zones [3][8]. Gallium Mineralization - Gallium was intersected from surface in all five holes, highlighting the near-surface character of the system and its strategic importance in advanced technologies [5][12]. - The presence of gallium is significant due to its critical role in semiconductors and other high-tech applications, with global supply being highly concentrated [5][20]. Geological Interpretation - The drilling results support the interpretation of a coherent and vertically developed supergene mineralized system formed through deep tropical weathering of granitic host rocks [9][10]. - The average spacing of approximately 380 meters between drill holes strengthens the interpretation of a laterally continuous mineralized system across a meaningful footprint [7][8]. Strategic Importance of the Arapaima Project - The Arapaima Project is located in Brazil's Lithium Valley, a region gaining international recognition for lithium and critical mineral discoveries, which aligns with global supply chain diversification efforts [17][18]. - As demand for magnet rare earths and gallium intensifies, Brazil's Lithium Valley continues to attract international attention as a prospective critical minerals district [20].

Core Viewpoint - A class action lawsuit has been filed against Mereo BioPharma Group PLC for allegedly making false and misleading statements regarding the success of its Phase 3 clinical trials for setrusumab, a treatment for Osteogenesis Imperfecta [1][2] Group 1: Lawsuit Details - The lawsuit includes all individuals and entities that purchased Mereo American Depositary Shares between June 5, 2023, and December 26, 2025 [1] - Investors have until April 6, 2026, to seek appointments as lead plaintiff [1][3] Group 2: Allegations Against Mereo - Investors allege that Mereo and certain executives expressed unwarranted confidence in the success of the ORBIT and COSMIC Phase 3 trials [2] - The company is accused of concealing adverse facts that contradicted their optimistic projections [2] Group 3: Trial Outcomes and Impact - On December 29, 2025, Mereo disclosed that neither the ORBIT nor COSMIC trials achieved statistical significance in reducing annualized fracture rates [3][7] - The share price plummeted from $2.31 to $0.29 in one trading session, representing a loss of over 87% of shareholder value [7]

Core Viewpoint - A class action lawsuit has been announced by Rosen Law Firm on behalf of purchasers of American Depositary Shares (ADS) of Mereo BioPharma Group plc, covering the period from June 5, 2023, to December 26, 2025, due to misleading statements regarding the company's clinical studies [1][5][6]. Group 1: Lawsuit Details - The lawsuit claims that Mereo BioPharma provided investors with optimistic information about the Phase 3 Orbit and COSMIC studies for setrusumab in Osteogenesis Imperfecta (OI), suggesting confidence in the drug's ability to reduce annualized fracture rates [5]. - It is alleged that while making these positive statements, Mereo BioPharma concealed material adverse facts about the Phase 3 programs, which ultimately did not meet their primary endpoints [6]. - The misleading information led to investors purchasing Mereo's ADSs at inflated prices, resulting in damages when the true state of the studies became known [6]. Group 2: Participation Information - Investors who purchased Mereo ADSs during the class period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, interested parties can visit the provided link or contact the law firm directly for more information [3][7].

Core Viewpoint - A class action lawsuit has been filed against Mereo BioPharma Group plc, alleging securities fraud and unlawful business practices related to the company's clinical trial results and stock price decline [1]. Group 1: Lawsuit Details - The class action lawsuit concerns whether Mereo and certain officers/directors engaged in securities fraud or other unlawful business practices [1]. - Investors who purchased Mereo securities during the Class Period have until April 6, 2026, to request to be appointed as Lead Plaintiff [1]. Group 2: Clinical Trial Results - On July 9, 2025, Mereo and Ultragenyx Pharmaceutical announced that the Phase 3 Orbit study was progressing toward a final analysis, which led to a 42.52% drop in Mereo's ADR price, closing at $1.69 per share on July 10, 2025 [1]. - On December 29, 2025, Mereo announced that neither the Orbit nor the Cosmic Phase 3 studies achieved statistical significance, resulting in an 87.7% decline in ADR price, closing at $0.29 per ADR [1].

Core Viewpoint - Mereo BioPharma Group plc is facing a class action lawsuit for securities law violations due to misleading statements regarding its Phase 3 clinical trials, which did not meet their primary endpoints, leading to a significant drop in stock price [1]. Summary by Relevant Sections Allegations - The lawsuit alleges that Mereo BioPharma provided overly positive statements while concealing material adverse facts about the Phase 3 ORBIT and COSMIC programs, which failed to achieve their primary endpoints of reducing annualized clinical fracture rates compared to placebo or bisphosphonate control groups [1]. - On December 29, 2025, Mereo announced that neither the ORBIT nor the COSMIC studies achieved statistical significance, despite improvements in bone mineral density [1]. Stock Price Impact - Following the announcement of the failed clinical trials, Mereo's American Depositary Shares (ADS) price plummeted from $2.31 per share on December 26, 2025, to $0.29 per share on December 29, 2025, marking a decline of over 87.7% [1]. Class Action Details - Shareholders who purchased Mereo shares during the class period from June 5, 2023, to December 26, 2025, are encouraged to contact the Gross Law Firm for potential lead plaintiff appointment, with a deadline set for April 6, 2026 [1]. - Participation in the class action does not require appointment as lead plaintiff, and there is no cost or obligation for shareholders to register [1].

Core Viewpoint - Mereo BioPharma Group plc is facing a class action lawsuit due to misleading statements regarding the Phase 3 ORBIT and COSMIC programs, which failed to meet their primary endpoints, leading to a significant decline in stock price [1][3]. Group 1: Class Action Details - The class action is on behalf of investors who purchased Mereo securities between June 5, 2023, and December 26, 2025, with a deadline for filing a lead plaintiff motion set for April 6, 2026 [1]. - Investors are encouraged to contact the Portnoy Law Firm for legal rights discussions and case evaluations [2]. Group 2: Program Failures - The complaint alleges that Mereo provided overly positive statements while concealing adverse facts about the Phase 3 ORBIT and COSMIC programs, which did not achieve their primary endpoints of reducing annualized clinical fracture rates [3]. - On December 29, 2025, Mereo announced that neither the ORBIT nor COSMIC studies achieved statistical significance, despite improvements in bone mineral density [3]. Group 3: Stock Price Impact - Following the announcement of the failed studies, Mereo's American Depositary Shares (ADS) price plummeted from $2.31 per share on December 26, 2025, to $0.29 per share on December 29, 2025, marking a decline of over 87.7% [3].

Core Viewpoint - Mereo BioPharma Group plc is facing a securities class action lawsuit due to alleged violations of federal securities laws related to misleading statements about its Phase 3 clinical trials, which failed to meet primary endpoints [1][1]. Group 1: Legal Action and Deadlines - Faruqi & Faruqi, LLP is investigating claims against Mereo BioPharma and reminds investors of the April 6, 2026 deadline to seek the role of lead plaintiff in the class action [1]. - The lawsuit alleges that Mereo and its executives made false or misleading statements regarding the Phase 3 ORBIT and COSMIC programs [1][1]. Group 2: Clinical Trial Results - Mereo announced on December 29, 2025, that two Phase 3 studies of setrusumab did not meet their primary endpoints of reducing annualized clinical fracture rates compared to placebo and bisphosphonates [1][1]. - Despite showing statistically significant improvements in bone mineral density on secondary endpoints, the failure to meet primary endpoints led to a negative market reaction [1]. Group 3: Stock Price Impact - Following the announcement of the failed trials, Mereo's stock price dropped by $2.02 per share, representing an 87.64% decline, closing at $0.28 per share on December 29, 2025 [1][1].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of American Depositary Shares of Mereo BioPharma Group plc, covering the period from June 5, 2023, to December 26, 2025, due to alleged misleading statements regarding the company's clinical programs [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Mereo BioPharma made false and/or misleading statements and concealed material adverse facts about the Phase 3 ORBIT and COSMIC programs, which did not meet their primary endpoints of reducing annualized clinical fracture rates compared to control groups [5]. - Investors who purchased Mereo securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Participation Information - Interested parties can join the class action by visiting the provided link or contacting the law firm directly for more information [3][6]. - A lead plaintiff must file a motion with the court by April 6, 2026, to represent other class members in the litigation [1][3]. Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - A class action has been filed against Mereo BioPharma Group plc for allegedly misleading investors regarding the Phase 3 ORBIT and COSMIC studies for setrusumab, which did not meet their primary endpoints [2][3] Group 1: Allegations and Misleading Information - The complaint alleges that Mereo BioPharma provided investors with overly optimistic statements about the expected results of the Phase 3 ORBIT and COSMIC studies, claiming confidence in setrusumab's ability to reduce annualized fracture rates [2] - It is claimed that while making these positive statements, Mereo concealed material adverse facts about the true state of the Phase 3 studies, which ultimately did not achieve their primary endpoints [2] - The studies failed to show a reduction in annualized clinical fracture rates compared to placebo or bisphosphonate control groups, leading to artificially inflated prices for Mereo's American Depository Shares (ADS) [2] Group 2: Impact of the Announcement - On December 29, 2025, Mereo announced that neither the ORBIT nor the COSMIC studies met their primary endpoint, resulting in a significant decline in the price of Mereo's ADS from $2.31 to $0.29, a drop of over 87.7% [3] Group 3: Class Action Participation - Shareholders may be eligible to participate in the class action against Mereo BioPharma, with a deadline to submit papers to serve as lead plaintiff by April 6, 2026 [4] - Shareholders do not need to participate in the case to be eligible for recovery and can remain absent class members if they choose [4]